IL2 and neoplasm: On the same line, ex vivo IL-2-activated NK cells were shown to be ineffective at inhibiting gastric cancer growth as a monotherapy; however, the combination with the anti-PD-1 antibody Nivolumab, administered as systemic therapy or as a pretreatment before NK cell infusion, greatly improved NK-cell-mediated anti-tumor response [174].